OASIS-3 tested elinzanetant for menopausal vasomotor symptoms. The primary week-12 result was positive; later symptom and sleep findings were descriptive.
Author: Hormone Insight Editorial Team
Read More
ATTAIN-MAINTAIN tested oral orforglipron after tirzepatide or semaglutide. More prior weight loss was retained than with placebo; continued injections were not compared.
TANDEM tested obicetrapib plus ezetimibe against placebo and each component over 84 days. Review LDL effects, adverse events and the outcomes limitation.
A small randomised bone-biopsy study examined denosumab, teriparatide and their combination. Mechanistic findings do not establish superior fracture prevention.
foresiGHt found improved body composition with weekly lonapegsomatropin versus placebo in adult growth hormone deficiency. The daily comparator was descriptive.
Bax24 found a 14.0 mm Hg placebo-corrected reduction in 24-hour systolic pressure at 12 weeks. Review the primary endpoint and hyperkalaemia signal.
A 25-person crossover trial studied dairy, meal timing and circadian genes in type 2 diabetes. Glycaemic changes were secondary and require cautious interpretation.
ORBIT found no composite responders with secukinumab or placebo in active Graves orbitopathy. Read the PICO, limitations and clinical implications.
A double-blind crossover RCT compared prednisolone and hydrocortisone. Review the bone-marker results, secondary metabolic findings and important safety limitations.
In a 16-week randomized study of women with obesity and PCOS, semaglutide improved taste recognition by an estimated 2.5 points versus placebo.